
Terray Therapeutics is an AI-powered biotechnology company focused on revolutionizing small molecule drug discovery. Their platform, tNova, uniquely integrates high-throughput chemical experimentation with computational analysis and generative AI. This approach emphasizes both wet lab science and AI to solve complex therapeutic challenges. Terray boasts an experimental dataset of over two billion binding measurements, growing by 300 million monthly, with each measurement supported by 25 independent data points for high-resolution quantitative data. Their closed-loop iteration cycle, completing in under a month, allows for rapid exploration of chemical space and experimental measurement of millions of molecules. Terray's internal pipeline targets immunology, and they partner with large pharma and biotech companies to apply their platform to a wide range of challenging targets and therapeutic areas.

Terray Therapeutics is an AI-powered biotechnology company focused on revolutionizing small molecule drug discovery. Their platform, tNova, uniquely integrates high-throughput chemical experimentation with computational analysis and generative AI. This approach emphasizes both wet lab science and AI to solve complex therapeutic challenges. Terray boasts an experimental dataset of over two billion binding measurements, growing by 300 million monthly, with each measurement supported by 25 independent data points for high-resolution quantitative data. Their closed-loop iteration cycle, completing in under a month, allows for rapid exploration of chemical space and experimental measurement of millions of molecules. Terray's internal pipeline targets immunology, and they partner with large pharma and biotech companies to apply their platform to a wide range of challenging targets and therapeutic areas.
What they do: AI-powered, chemistry-first platform (tNova / EMMI) for small-molecule drug discovery combining high-throughput experimental chemistry and generative AI
Data scale: Experimental dataset of over two billion target–ligand binding measurements, growing rapidly
Funding: Raised >$200M total; $120M Series B announced Oct 17, 2024
Focus areas: Internal immunology programs and partnered programs with large pharma
| Company |
|---|
Small-molecule drug discovery, particularly challenging targets in immunology and partnered pharma programs.
2018
Biotechnology Research
120000000
Announced as an oversubscribed round; brought total equity financing to over $200M.
60000000
20000000
“Syndicate includes institutional and strategic investors (e.g., Bedford Ridge Capital, NVentures/NVIDIA, Madrona, Two Sigma Ventures, Digitalis Ventures, XTX Ventures, Goldcrest Capital, Alexandria Venture Investments)”
Company Overview: Terray Therapeutics is a venture-backed biotechnology company led by pioneers and long-time leaders in artificial intelligence, synthetic chemistry, automation, and nanotechnology. We’re generating chemical data purpose-built to propel drug discovery into the information age — and we’re doing it on a larger scale and faster than has ever before been possible.
Our closed loop system generates precise chemical datasets at unrivaled scale that work seamlessly with AI to systematically map biochemical interactions between small molecules and causes of disease. Iterative cycles of virtual molecular design and experimentation power AI and machine learning models, which in turn guide the next cycle of design. With a chemistry engine that measures billions of interactions daily and becomes increasingly precise with every cycle, we can answer an unprecedented array of questions — deriving insights that enable us to predictably create drugs for patients in need.
Terray Therapeutics is seeking a highly motivated, creative, and experienced immunologist to join our biology team. This is a strategic role working closely with the CSO and other leads in the preclinical team and across the company to support our small-molecule pipeline. In this role, the Associate Director will lead the team responsible for all cell-based assay development and execution, including hit validation, structure-activity relationships, and lead optimization. The candidate will provide immunology expertise to evaluate new targets and expand our internal pipeline programs. They will be a pivotal collaborator within a multidisciplinary team. The successful candidate will have a strong background in assay development for inflammation targets in the context of small molecule drug discovery. This role will be full-time, onsite, and will report to the CSO.
The Core Responsibilities Of This Position Are
Lead a small, highly motivated team of assay scientists who develop and run cell assays in support of internal and partner pipeline programs
Work closely with scientists across the company in biology, chemistry, platform, screening, data, and computational teams to efficiently advance projects from hit validation through hit-to-lead and lead optimization to lead candidate selection
Develop cell-based assay funnels to support structure-activity optimization for our inflammation target portfolio as programs progress to hit-to-lead and lead optimization
Expert understanding of inflammatory pathways as they relate to the target and disease mechanism
Analyze and interpret experimental data and communicate results in project team meetings
Experience and Qualifications: Part of Terray’s success is nurtured by a hands-on work environment where everyone is accountable, vested in a vision of excellence, and actively taking part in the success of the business. Terray supports a positive work environment where employees can feel engaged, recognized, and empowered to be creative. They will exhibit the ability to work well under pressure to provide results in a short timeframe. The company is looking for a highly responsive, goal-oriented individual who will bring significant energy and drive to solve complex technical problems and help us achieve our mission to advance human health.
Required Qualifications
Preferred Qualifications
Compensation Details: $180,000 - $263,000 (annually) depending on skill level; participation in the Company's option plan; 3% retirement safe harbor contribution; fully-paid medical, dental, vision, life, and disability benefits.